Answers are grounded in this paper and cite their sources.
This biological proof-of-concept study finds ustekinumab improves outcomes in bullous pemphigoid, indicating a potential role of biomarkers in treatment response.
We report promising clinical outcomes using ustekinumab as a first-line therapy in bullous pemphigoid (BP) when combined with a short, 8-week regimen of super-potent topical corticosteroids. Furthermore, the CD40L/IL-4 ratio emerged as a potential predictive biomarker of treatment response, possibly reflecting a Th1-skewed immune environment that favors ustekinumab’s mechanism of action.
No takes yet. Share an insight, caveat, or question.
Koliadenko et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: